{"id":389315,"date":"2022-12-27T00:00:00","date_gmt":"2022-12-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/conccg0004-2022-biopharma-parkinsons-disease-geographic-focus-china-parkinsons-disease-china-in-depth-china\/"},"modified":"2026-03-31T10:35:29","modified_gmt":"2026-03-31T10:35:29","slug":"conccg0004-2022-biopharma-parkinsons-disease-geographic-focus-china-parkinsons-disease-china-in-depth-china","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/conccg0004-2022-biopharma-parkinsons-disease-geographic-focus-china-parkinsons-disease-china-in-depth-china\/","title":{"rendered":"Parkinson&#8217;s Disease &#8211; Geographic Focus: China &#8211; Parkinson&#8217;s Disease &#8211; China In-Depth (China)"},"content":{"rendered":"<p>Parkinson\u2019s disease is a chronic neurodegenerative disease characterized by progressively worsening motor symptoms. Treatment of Parkinson\u2019s disease in China comprises a broad range of symptomatic therapies including<span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"2\" data-last-change-time=\"1671534709122\" data-time=\"1671534709122\" data-userid=\"35805\" data-username=\"Sabah\">,<\/span> dopamine precursors, dopamine agonists, MAO-B inhibitors, and COMT inhibitors. The expected imminent approval of safinamide\u2014the third-to-market MAO-B inhibitor\u2014and LY03003\u2014the reformulation of rotigotine, a dopamine agonist, that offers a more convenient once-weekly dosing advantage\u2014have the potential to meaningfully change the treatment paradigm of Parkinson\u2019s disease in China. The uptake of these therapies, in addition to the growing aging-led prevalence of the disease in the country, will lead to significant growth of the Parkinson\u2019s disease market of China during the 2021-2031 period. Additionally, in view of the ongoing reforms in China\u2019s regulatory and access and reimbursement landscape, multinational companies will be increasingly encouraged to enter this market.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul>\n<li>How large is China\u2019s drug-treatable Parkinson\u2019s disease population, and how will the drug-treatment rate change during the forecast period?<\/li>\n<li>What are the most commercially relevant drugs in China\u2019s Parkinson\u2019s disease market<span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"3\" data-last-change-time=\"1671534773584\" data-time=\"1671534773584\" data-userid=\"35805\" data-username=\"Sabah\">,<\/span> and why? What are interviewed experts\u2019 insights into current treatment options? Which clinical needs remain unfulfilled?<\/li>\n<li>What are the key market access considerations for key therapies in the Parkinson\u2019s disease pipeline of China? What sales<span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"4\" data-last-change-time=\"1671534792086\" data-time=\"1671534792086\" data-userid=\"35805\" data-username=\"Sabah\"> <\/span>\/<span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"5\" data-last-change-time=\"1671534792335\" data-time=\"1671534792335\" data-userid=\"35805\" data-username=\"Sabah\"> <\/span>uptake could they secure in Parkinson\u2019s disease?<\/li>\n<li>What are the key drivers and constraints in the Chinese Parkinson\u2019s disease market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Geography: China<\/p>\n<p>Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 neurologists<\/p>\n<p>Epidemiology: Diagnosed prevalence of Parkinson\u2019s disease in urban versus rural China; clinically relevant and market-relevant drug-treatable populations<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient shares of key heart failure therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions<\/p>\n<p><strong>Product Description <\/strong><\/p>\n<p><em>China In-Depth <\/em>offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&#038;R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<span class=\"ice-ins ice-cts-1\" data-changedata=\"\" data-cid=\"6\" data-last-change-time=\"1671534852861\" data-time=\"1671534852861\" data-userid=\"35805\" data-username=\"Sabah\"> <\/span>This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.<\/p>\n","protected":false},"template":"","class_list":["post-389315","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-neurology","biopharma-therapy-areas-parkinsons-disease","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389315\/revisions"}],"predecessor-version":[{"id":576147,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389315\/revisions\/576147"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}